129 related articles for article (PubMed ID: 16113755)
21. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P
Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838
[TBL] [Abstract][Full Text] [Related]
22. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis.
Sirén V; Kauhanen P; Carpén O; Luther M; Lepäntalo M; Vaheri A; Lassila R
Blood Coagul Fibrinolysis; 2003 Jun; 14(4):369-77. PubMed ID: 12945879
[TBL] [Abstract][Full Text] [Related]
23. The plasminogen-activation system in ovarian tumors.
Pujade-Lauraine E; Lu H; Mirshahi S; Soria J; Soria C; Bernadou A; Kruithof EK; Lijnen HR; Burtin P
Int J Cancer; 1993 Aug; 55(1):27-31. PubMed ID: 8344749
[TBL] [Abstract][Full Text] [Related]
24. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Cancer; 1996 Mar; 77(6):1035-43. PubMed ID: 8635120
[TBL] [Abstract][Full Text] [Related]
26. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E
Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
[TBL] [Abstract][Full Text] [Related]
27. Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid.
Kinnby B; Matsson L; Astedt B
J Periodontal Res; 1996 May; 31(4):271-7. PubMed ID: 8814598
[TBL] [Abstract][Full Text] [Related]
28. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis.
Gissler HM; Frank R; Kramer MD
Br J Dermatol; 1993 Jun; 128(6):612-8. PubMed ID: 7687853
[TBL] [Abstract][Full Text] [Related]
30. Co-localization of urokinase and its receptor on established human umbilical vein endothelial cell.
Ueshima S; Matsumoto H; Izaki S; Mitsui Y; Fukao H; Okada K; Matsuo O
Cell Struct Funct; 1999 Apr; 24(2):71-8. PubMed ID: 10362070
[TBL] [Abstract][Full Text] [Related]
31. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
[TBL] [Abstract][Full Text] [Related]
32. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
33. Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels.
Falkenberg M; Tjärnström J; Ortenwall P; Olausson M; Risberg B
Thromb Haemost; 1996 Jun; 75(6):933-8. PubMed ID: 8822589
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
36. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Sier CF; Verspaget HW; Griffioen G; Verheijen JH; Quax PH; Dooijewaard G; De Bruin PA; Lamers CB
Gastroenterology; 1991 Dec; 101(6):1522-8. PubMed ID: 1955118
[TBL] [Abstract][Full Text] [Related]
37. Evidence for an active fibrinolytic system in normal human bone marrow.
McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence.
West MD; Shay JW; Wright WE; Linskens MH
Exp Gerontol; 1996; 31(1-2):175-93. PubMed ID: 8706787
[TBL] [Abstract][Full Text] [Related]
39. Quantitative evaluation of the influence of ovarian steroids on plasminogen activators and inhibitors in human endometrial cells and trophoblasts.
Ueyama M; Kasatori N; Urayama T; Maemura T; Yao Y; Shiraishi T; Saito S; Kubo H
Thromb Res; 2002 Nov; 108(4):235-44. PubMed ID: 12617987
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB
Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
